Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Walgreen Does it Right

By Michael Lewis - Mar 27, 2014 at 1:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Profits may have taken a short-term hit due to cyclical events and some bad weather, but this is one great company.

The market has been relentless in punishing stocks that miss expectations, whether it's due to blizzards on the East Coast or more internal factors. Walgreen ( WBA 4.28% ), though, can apparently do no wrong. The drug store chain this week missed quarterly profit expectations, yet shares still rallied as Walgreen did achieve record sales and a record number of prescriptions filled. Walgreen and its peers have a perennial wind at their backs with more people taking more medication all the time. One of the big keys to keeping investors and analysts happy has been improving the front of the store, where margins are lower but retail space abounds. Is Walgreen as desirable as the market thinks?

Solid quarter
Sales climbed slightly more than 5% to a record $19.6 billion in Walgreen's fiscal 2014 second quarter, driven largely by an appetizing 4.3% climb in same-store sales. These are especially promising figures, as many retailers took a hit due to weather conditions in recent months, and the recurring patent cliff (in which branded drugs become generic ones -- a great turn for drug stores given the higher profit margins of generics) is at a sluggish point, keeping additional margin pressure on prescriptions.

Like many private label versus branded goods, retailers purchase generic pharmaceuticals at a much lower price than their Pfizer, Merck, and other major drug-maker counterparts. The drugs, which can be sold at much lower costs to the consumer, often see increased demand.

The bottom line felt the margin pressures, as earnings dropped an adjusted 5.2% to $0.91 per share. For one thing, the patent cliff was at a peak in the first quarter of last year, making this year an especially difficult comp in addition to being a low point in the cycle. Why would last year's first quarter affect this year's second?--The peak of last year's Q1 carried sales higher through Q2. 

The market didn't care, and appropriately so. Walgreen has plenty of long-term bullish indicators to make the year-over-year drop a nonevent. The patent cliff situation should cycle back into positive territory by the last leg of 2014. In the meantime, Walgreen is keeping costs controlled and continuing to focus on increasing the profitability of the front of store. Front-end comps were up 2% in the recent quarter, which again reinforces the effort in light of extreme weather. Average basket sizes are increasing, and the company is capturing greater market share in the daily living category.

Anything not to like?
From an operational and managerial point of view, Walgreen leaves little on the table. The company's retail pharmacy market share is nearly 20%. Its stake in European pharmacy juggernaut Alliance Boots (a $6.7 billion deal sealed midway through 2013) is on track to deliver better synergies than previously thought.

Interestingly, the company intends to close 76 locations throughout the year. For a company whose strategy is basically to have stores on every corner in America, it's refreshing to see some attention to store-level performance. Management noted that it was looking over density data, real estate positioning, and trends in the stores' immediate areas. Despite its 8,000+ retail footprint, the company seems to have its finger on the pulse of each individual store.

At 17 times earnings, investors aren't getting a bargain on shares, but they are buying a company with great long-term potential. At the current level, Walgreen stock has its fair share of downside risk, but growth seekers should pay close attention. This is one of an increasingly few brick-and-mortar businesses that is only going up.

 
 
 
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$46.53 (4.28%) $1.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.